TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients willing and able to provide voluntary written informed consent and to follow the protocol specific requirements.~* Male or female patients over 18 years old.~* Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected within 7 days prior to enrollment) who are admitted or being admitted to the hospital for a primary diagnosis of COVID-19.~* In the case of female patients of child-bearing potential, a negative blood pregnancy test prior to beginning the therapy.~* Patients intended to be hospitalized to receive SOC including dexamethasone treatment for COVID-19.~Exclusion Criteria:~Exclusion Criteria:~* Patients with evidence of other serious infections.~* Malignancy.~* Background disease which, in the opinion of the investigator prevents the patient from participating in the study such as:~  * Presence of serious chronic infectious.~ * A condition resulting in immunodeficiency.~ * Participants with glucose levels upon admission ≥ 250 mg/dL~ * Acute psychosis~* Patients in a critical stage of COVID-19 disease that require mechanical ventilation.~* Pregnant and lactating women.~* Patients that are currently or have participated in other clinical studies with investigational drug, biological agent, or device within 1 month or within 5 half-lives (of the drug/biologic) prior to enrollment (whichever is longer).~* Patient currently receiving chemotherapy or immunosuppressive agents not including dexamethasone within 30 days before the screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COVID-19 Patients (Type: EXPERIMENTAL): Moderate to severe COVID-19 patients receiving SOC and '005.
- Control (Type: PLACEBO_COMPARATOR): Moderate to severe COVID-19 patients receiving SOC and placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Provide informed consent from a competent custodial parent or guardian with legal capacity to execute a local Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved consent. In addition, informed assent will be sought from capable subjects, in accordance with the directive of the institution's IRB/IEC and all other local requirements.~2. Be male and ≤17 years of age at the time of treatment, for retrospective and partial prospective/retrospective subjects, or at the time of parental/guardian consent and, where appropriate, subject assent, for prospective subjects.~3. Have a confirmed diagnosis of CALD as defined by abnormal VLCFA profile and cerebral lesion on brain MRI.~4. Depending on the cohort, the subject must:~   * Be scheduled for allo-HSCT evaluation at a study site (prospective cohort only),~  * Have received an allo-HSC infusion and be consented in time to complete the Month 24 Visit on study (partial prospective/retrospective cohort only), or~  * Have received their most recent allo-HSC infusion on or after January 1, 2013 (retrospective cohort only).~Exclusion Criteria:~1. Previous treatment with a gene therapy product.~2. Receipt of an experimental transplantation procedure.

- Gender: MALE
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Allo-HSCT prospective (Type: None): Subjects who will be consented before they received an allo-HSC infusion. They will be consented and enrolled on the study during the Screening Period.
- Allo-HSCT partial prospective/retrospective (Type: None): Subjects who will be consented after they received an allo-HSC infusion but before they reach 24 months post-infusion on study. Subjects in this cohort will participate prospectively in at least the Month 24 Visit in order to obtain prospective on-study data for this and all visits after Month 24
- Allo-HSCT retrospective (Type: None): Subjects who received an allo-HSC infusion on or after January 1, 2013 and died before study data collection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Persantine: Variation in Response Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \> 21 years old~* Patient undergoing cardiac catheterization with planned PTCA or with a significant coronary lesion of either the LAD or Circumflex~Exclusion Criteria:~* Theophylline or oral Persantine use in 24hrs~* Second or third degree AV block, or sick sinus syndrome without a functioning pacemaker~* Active asthma or bronchospasm~* Patients with severe hepatic insufficiency~* Patients experiencing an acute transmural infarction at the time of the index visit~* Conditions that are known to affect resistive vessel function or myocardial flow

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All subjects receive dipyridamole (Type: OTHER): Compare to baseline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Probiotic Visbiome for Inflammation and Translocation in HIV Ι

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV-1 infection~* Male adult (age \>18 years)~* Antiretroviral therapy-naïve~* Ability to provide informed consent~* HIV-1 viral load ≥1,000 copies/ml~Exclusion Criteria:~* Current alcohol or substance use judged by the Investigator to potentially interfere with participant study compliance~* Taking pharmaceutical grade probiotics~* Any of the following abnormal laboratory results in screening:~  * Hemoglobin \<85 g/L~ * Neutrophil count \<750 cells/μl~ * Platelet count \<50,000 cells/μl~ * AST or ALT \>5X the upper limit of normal~* Malignancy~* Colitis~* Liver fibrosis (decompensated cirrhosis), portal hypertension or clinical hepatitis~* Other significant underlying disease (non-HIV-1) that might impinge upon disease progression or death

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Probiotic Group (Type: EXPERIMENTAL): Visbiome experimental group (900 billion bacteria daily; 2 sachets daily)
- Placebo Group (Type: PLACEBO_COMPARATOR): Placebo comparator group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effectiveness of the Addition of Dexmedetomidine to Analgesia for Ankle Surgery.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English Speaking~* American Society of Anesthesiologists (ASA) I-III patients~* Ages 18-65~* Body Mass Index (BMI) ≤ 38 kg/m2~Exclusion Criteria:~* Preexisting neurological deficits or peripheral neuropathy in the distribution of the sciatic or femoral nerves~* Known coronary heart disease, congestive heart failure, cardiomyopathies, or arrhythmias~* Baseline line heart rate \< 60 Beats Per Minute (BPM) or baseline systolic blood pressure \< 100 mm Hg~* Medications that reduce heart rate~* Known liver or renal dysfunction or existing diseases affecting these organs~* Local infection~* Contraindication to regional anesthesia~* Chronic pain disorders~* History of use of over 30mg oxycodone or equivalent per day~* Contraindication to a component of multi-modal analgesia~* Allergy to local anesthetics or dexmedetomidine~* History of significant psychiatric conditions that may affect patient assessment~* Pregnancy~* Inability to provide informed consent~* Patient refusal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dex 0.5 (Type: EXPERIMENTAL): Ropivacaine and Lidocaine plus Dexmedetomidine (0.5mg/kg) plus Normal Saline
- Dex 1.0 (Type: EXPERIMENTAL): Ropivacaine and Lidocaine plus Dexmedetomidine (1.0mg/kg) plus Normal Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does the Wording of Text Message Reminders Improve Uptake in Breast Screening?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women who are eligible and due for breast screening in West London.~Exclusion Criteria:~* Women who are not eligible for breast screening due to for example bilateral mastectomies.~* Women who have chosen to not have screening and have informed the screening centre or their GP.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): The current standard care text message reminder (SMS) that women routinely receive when being invited for their breast screening mammogram will be sent to the control group at 7 and 4 days before their timed appointment.
- Intervention A - Behavioural Regulation (Type: EXPERIMENTAL): Intervention A will be a text message reminder (SMS) containing a behavioural regulation message. Women will be sent this SMS at 7 and 4 days prior to their timed appointment.
- Intervention B - Priority (Type: EXPERIMENTAL): Intervention B will be a text message reminder (SMS) containing a priority message. Women will be sent this SMS at 7 and 4 days prior to their timed appointment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented SARS-CoV-2 infection by qPCR assay performed within the past 7 days~Exclusion Criteria:~* COVID-19 symptoms requiring hospitalization~* PO2 \< 92%~* Short of breath at time of enrollment~* Retinal eye disease~* Known glucose-6 phosphate dehydrogenase (G-6-PD) deficiency~* Known chronic kidney disease, stage - 5 or receiving dialysis~* Current use of:~  * Class 3 AAD (amiodarone, dronaderone, dofetilide, sotalol)~ * Class 1A AAD (procainamide, quinidine, disopyramide)~ * Flecainide~ * SSRI: citalopram (Celexa), Escitalopram (Lexapro)~ * chlorpromazine~ * Cilostazol (Pletal)~ * Donepezil (Aricept)~ * Droperidol~ * Fluoconazole~ * Methadone~ * Ondansetron (Zofran)~ * Thioridazine~ * Macrolides (clarithromycin, erythromycin)~ * Fluroquinolones (ciprofloxacin, levofloxacin, moxifloxacin)~ * Tamoxifen~* Pregnancy or women who are breast feeding~* Inability to tolerate oral medications~* Allergy or prior adverse reaction to either hydroxychloroquine sulfate, ribavirin, or nitazoxanide~* Allergy to adhesives~* QTc interval \> 450 mSEC for men and women~* History of Torsade de Pointes VT or prior cardiac arrest or congenital long QT interval~* Non-English-speaking

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Study Drug (Type: ACTIVE_COMPARATOR): 5 day dosing of Nitazoxanide, Ribavirin \& Hydroxychloroquine sulfate
- Placebo (Type: PLACEBO_COMPARATOR): 5 day dosing of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multi-level Interventions for STD Prevention Among Adolescents

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Student at participating school~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 20 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 14 and younger than 65 years old~* Skin lesions with clinical suggestion of cutaneous leishmaniasis and positive leishmanin skin test(Montenegro test)or parasitological (direct observation of leishmania amastigotes, leishmania in vitro culture from aspirates, histopathological) and molecular(Polymerase Chain Reaction - PCR)samples.~* No use of oral potentially antileishmanial drugs, or topics throughout the term of the current injury.~* Absence of disseminated leishmaniasis.~* Absence of mucosal involvement.~* Agreement to participate in the study and signed the informed consent.~Exclusion Criteria:~* Diabetes mellitus, kidney diseases, liver or cardiac diseases, tuberculosis, malaria.~* Pregnancy~* lactating mothers~* Breast feeding~* Cutaneous lesion with bacterial infection for which antibiotics need to be prescribed~* More than six cutaneous lesions~* Previous history of cutaneous or mucosal leishmaniasis~* Use of drugs with potential pharmacological interactions with antimonials as anti-arrhythmic or tricycle anti-depressives~* Previous intolerance to azithromycin or other macrolides or N-methylglucamine~* Abusive alcohol ingestion according to the CAGE questionnaire

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A - N- methyl glucamine (Type: ACTIVE_COMPARATOR): Glucantime® , max day of 1,215 mg
- B - Azithromycin (Type: EXPERIMENTAL): Zithromax ® , one dose 500 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Validation of Low Dose CT for Diagnosis of Urolithiasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric and young adult patients (ages 4 to \<21 years)~* Known or suspected urolithiasis~* Undergoing clinically indicated CT of the abdomen/pelvis~Exclusion Criteria:~* Pregnancy~* Prior enrollment in the same study (no patient will be enrolled more than once)

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Study Group (Type: EXPERIMENTAL): Patients will receive both the clinically indicated and extremely low dose CT exams

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed diagnosis of NSCLC.~2. Stage IIIA or IIIB NSCLC.~3. Patients must have no evidence of metastatic disease based on routine imaging.~4. Patients must have a Karnofsky Performance Status of 60.~5. Age 18 and older.~6. Patients must be able to provide informed consent.~7. Adequate bone marrow function (i.e. WBC larger than or equal to 4000/mm3, platelets larger than or equal to 100,000 mm3).~8. Adequate renal function for cisplatin or carboplatin as determined by the medical oncologist: Usually Calculated creatinine clearance (CrCl) larger than or equal to 45 mL/min or serum creatinine level smaller than or equal to1.5 x institutional ULN.~9. Patients must have bilirubin 1.5 mg/dl.~10. Women of child-bearing potential as long as she agrees to use a recognized method of birth control (e.g. oral contraceptive, IUD, condoms or other barrier methods etc).~11. Hysterectomy or menopause must be clinically documented.~Exclusion Criteria:~1. Prior or simultaneous malignancies within the past two years (other than cutaneous squamous or basal cell carcinoma or melanoma in situ).~2. Pregnant women, women planning to become pregnant and women that are nursing.~3. Actively being treated on any other research study.~4. For the Nelfinavir phase of the trial only: Patients who are taking Antiarrhythmics (amiodarone, quinidine), Antimycobacterial (rifampin), Ergot Derivatives (dihydroergotamine, ergonovine, ergotamine, ethylergonovine), Herbal Products (St. John's wort/ hypericum perforatum), HMG-CoA Reductase Inhibitors (lovastatin, simvastatin), Neuroleptic (pimozide), Proton Pump Inhibitors, or Sedative/ Hypnotics (midazolam, triazolam). Note: Patients with the following conditions are deemed unsuitable for cisplatin-based chemotherapy (and will be treated with carboplatin): (a) Hearing impairment/ peripheral neuropathy Grade 1 or less at baseline (b) Symptomatic/uncontrolled congestive heart failure (unable to tolerate volume load with pre- and post-cisplatin hydration)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Proton RT and Nelfinavir (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Influence of Daily Strawberry Intake on Vascular Health in Elderly Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is willing and able to comply with the study protocols.~* Subject is willing to participate in all study procedures~* BMI 25.0 - 35 kg/m2~Exclusion Criteria:~* BMI ≥ 35 kg/m2~* Visit 1 Reactive Hyperemia Index (RHI; EndoPAT 2000) ≥ 2.8~* Dislike or allergy strawberries~* Self-reported use of daily anticoagulation agents including aspirin, NSAIDs~* Prescription medications other than on a 6 month self-reported stable dose of medications for lipid lowering and/or hypertension.~* Vegan, Vegetarians, food faddists or those consuming a non-traditional diet~* Fruit consumption ≥ 3 cups/day~* Regular consumption of strawberries (2-3 servings/week)~* Vegetable consumption ≥ 4 cups/day~* Coffee/tea ≥ 3 cups/day~* Dark chocolate ≥ 3 oz/day~* Self-reported restriction of physical activity due to a chronic health condition~* Self-reported chronic/routine high intensity exercise~* Self-reported diabetes~* Blood pressure ≥ 140/90 mm Hg~* Self-reported renal or liver disease~* Self-reported heart disease, which includes cardiovascular events and stroke~* Peripheral artery disease Raynaud's syndrome or disease~* Inability to properly place or wear the PAT probes or abnormal measurements on pre- screening PAT~* Abnormal Metabolic or CBC panels (laboratory values outside the reference range) if determined to be clinically significant by the study physician.~* Self-reported cancer within past 5 years~* Self-reported malabsorption~* Supplement use other than a general formula of vitamins and minerals that meet the RDA~* Not willing to stop any supplement use, including herbal, plant or botanical, fish oil, oil supplements a month prior to study enrollment.~* Indications of substance or alcohol abuse within the last 3 years~* Cannabis use~* Current enrollee in a clinical research study.

- Gender: MALE
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Freeze dried strawberry powder (Type: EXPERIMENTAL): 39g of freeze dried strawberry powder, which represents three daily servings of strawberries.~The powder will be mixed in one cup of water.
- control powder (Type: PLACEBO_COMPARATOR): 39 g of a powder that matches the sugar and caloric content of the experimental powder. The powder will be mixed in one cup of water.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues